Studies have found increased risks of gastrointestinal adverse events (biliary disease, pancreatitis, bowel obstruction, and gastroparesis5) with Glucagon like Peptide 1 agonist (GLP-1) use in patients with diabetes. 1-4
This study found that use of GLP-1 agonists for weight loss compared with use of bupropion-naltrexone was associated with increased risk of pancreatitis, gastroparesis, and bowel obstruction but not biliary disease.
Ozempic is approved for type 2 diabetes, but it's often used for weight loss. It's been gaining in popularity pretty quickly, and it's not just Ozempic. We know that those prescriptions for weight loss drugs have really soared. There was a report released last Wednesday that came from Trillium Health, which is a data analytics firm. And it showed that health care providers were more—wrote more than 9 million prescriptions for Ozempic and similar drugs in the final three months of 2022.
Ziel der Studie war es, die Wirksamkeit und Sicherheit von endoskopischer Sleeve-Magenverkleinerung (Endosleeve) in Kombination mit Lebensstiländerungen im Vergleich zu Lebensstiländerungen allein zu untersuchen.
In der Studie wurden 209 freiwillige Studienteilnehmer zufällig in 2 Gruppen, Ernährungsumstellung plus Endosleeve sowie Ernährungsumstellung (Diät) alleine (1:1,5) eingeteilt.